News and features

Articles

Showing 31 - 40 of 1123

News & Analysis

LAWYER OF THE MONTH - FEBRUARY 2025

19 February 2025 by asialaw

asialaw's Lawyer of the Month for February 2025 is...

News & Analysis

asialaw 2025 Research Cycle Now Open

18 February 2025 by asialaw

The submission deadline is 11 April, 2025.

News & Analysis

Selected 2025 Tax Amendments

14 February 2025 by Lee & Ko

In December 2024, the Korean National Assembly enacted and finalized the 2025 Tax Law amendment proposals into Law (Tax Law Amendments)

News & Analysis

Shardul Amarchand Mangaldas & Co.’s former Partner Tejas Karia has been appointed as a judge of the Delhi High Court

14 February 2025 by Shardul Amarchand Mangaldas & Co

Hon’ble Mr. Justice Tejas Karia, has been appointed as a Judge of the Hon’ble High Court of Delhi

News & Analysis

KFTC 2025 Annual Work Plan

07 February 2025 by Lee & Ko

The KFTC has announced its ‘2025 Annual Work Plan’ which identifies key tasks to restore the civil economy and to create a fair trade foundation for future-proofing

News & Analysis

Shardul Amarchand Mangaldas & Co. is advising Access Healthcare on a Growth Investment from New Mountain Capital

06 February 2025 by Shardul Amarchand Mangaldas & Co

31 January 2025 | New Delhi: Shardul Amarchand Mangaldas & Co. is advising Access Healthcare, a leading technology-enabled platform for revenue cycle management (RCM), in a strategic investment from affiliates of New Mountain Capital, LLC .

News & Analysis

Health in Transition Part 3: Indonesia's New Tobacco and E-Cigarette Regulations

27 January 2025 by

Indonesia has long grappled with public health concerns tied to tobacco and other addictive substances.

News & Analysis

DEAL OF THE MONTH - JANUARY 2025

21 January 2025 by asialaw

asialaw's Deal of the Month for January 2025 is...

News & Analysis

LAWYER OF THE MONTH - JANUARY 2025

21 January 2025 by asialaw

asialaw's Lawyer of the Month for January 2025 is...

News & Analysis

Six Key Insights into China Biotech’s NewCo Model

20 January 2025 by

China’s pharmaceutical industry is witnessing a notable surge in “pipeline spin-off projects”, a model commonly referred to as the "Spin-off-NewCo" or "SON" model.